Trexquant Investment LP Buys New Shares in OptimizeRx Corp. $OPRX

Trexquant Investment LP purchased a new position in shares of OptimizeRx Corp. (NASDAQ:OPRX - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 54,262 shares of the company's stock, valued at approximately $470,000. Trexquant Investment LP owned 0.29% of OptimizeRx as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of OPRX. Wells Fargo & Company MN boosted its stake in shares of OptimizeRx by 33.3% during the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock worth $54,000 after acquiring an additional 2,797 shares in the last quarter. Barclays PLC increased its holdings in shares of OptimizeRx by 13.5% during the 4th quarter. Barclays PLC now owns 30,574 shares of the company's stock worth $148,000 after buying an additional 3,640 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of OptimizeRx by 9.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 444,167 shares of the company's stock worth $2,159,000 after buying an additional 39,740 shares during the last quarter. Northern Trust Corp increased its holdings in OptimizeRx by 3.3% in the 4th quarter. Northern Trust Corp now owns 189,044 shares of the company's stock valued at $919,000 after purchasing an additional 6,043 shares during the last quarter. Finally, Jane Street Group LLC increased its holdings in OptimizeRx by 234.7% in the 4th quarter. Jane Street Group LLC now owns 72,454 shares of the company's stock valued at $352,000 after purchasing an additional 50,808 shares during the last quarter. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Price Performance

OPRX opened at $18.29 on Tuesday. The company has a fifty day simple moving average of $15.01 and a 200 day simple moving average of $11.57. The firm has a market cap of $339.65 million, a price-to-earnings ratio of -33.87 and a beta of 1.20. OptimizeRx Corp. has a twelve month low of $3.78 and a twelve month high of $19.25. The company has a current ratio of 2.57, a quick ratio of 2.57 and a debt-to-equity ratio of 0.21.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on OPRX shares. Citigroup reissued an "outperform" rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Wall Street Zen raised shares of OptimizeRx from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Stifel Nicolaus lifted their price objective on shares of OptimizeRx from $16.00 to $18.00 and gave the company a "buy" rating in a research note on Friday, August 8th. B. Riley reiterated a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Finally, Roth Capital reissued a "buy" rating on shares of OptimizeRx in a report on Friday, August 8th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $11.81.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.